Vertex Pharmaceuticals (NASDAQ: VRTX)
Vertex Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Vertex Pharmaceuticals Company Info
Vertex is in the business of discovering, developing, and commercializing small-molecule drugs for the treatment of serious genetic diseases including cystic fibrosis.
News & Analysis
Stock Market Whiplash: 3 Growth Stocks That Are No-Brainer Buys on the Bounce
We're About to Find Out the Answer to Warren Buffett's Pointed Question About Trump's Tariffs. Here Are 3 Stocks to Buy Depending on What That Answer Is.
Is Vertex Pharmaceuticals Stock a Buy?
2 Stocks to Buy if You're Worried About a Recession
Biotech vs Pharma: What's the Difference?
Investing in Gene-Editing Stocks
3 Unstoppable Stocks You Can Buy Now Without Any Hesitation
Where Will Vertex Pharmaceuticals Be in 10 Years?
Valuation
Podcast Episodes
Alleged Industrial Espionage Makes an Interesting Story
We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment.
3 Biotech Companies Analyzed
We examine three biotech companies' past performances and future outlooks.
Is Amarin's Fish Oil Pill on Track to Become a Blockbuster?
Plus, how gene-editing company CRISPR Therapeutics just took a big step forward.
Earnings Transcripts
Vertex Pharmaceuticals (VRTX) Q4 2024 Earnings Call Transcript
VRTX earnings call for the period ending December 31, 2024.
Vertex Pharmaceuticals (VRTX) Q3 2024 Earnings Call Transcript
VRTX earnings call for the period ending September 30, 2024.
Vertex Pharmaceuticals (VRTX) Q2 2024 Earnings Call Transcript
VRTX earnings call for the period ending June 30, 2024.
Vertex Pharmaceuticals (VRTX) Q1 2024 Earnings Call Transcript
VRTX earnings call for the period ending March 31, 2024.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.